Ideational Fluency in Patients with Rheumatoid Arthritis

Author(s): Janis Mednieks*, Vladimrs Naumovs, Jurgis Skilters

Journal Name: Current Rheumatology Reviews

Volume 17 , Issue 2 , 2021


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Neuropsychiatric symptoms have been well documented in several systemic inflammatory conditions, for example, systemic lupus erythematosus (SLE). Increased prevalence of cognitive decline and psychiatric issues has been reported in patients with rheumatoid arthritis (RA). However, there is limited evidence of which exact cognitive domains are affected and to what degree.

Aim: To test the performance of cognition in the domain of ideational fluency (Thing Categories Test in particular) in patients with RA and compare the results with the general population and to the results with cognitive and depression screening scores in both groups.

Methods: Patient Health Questionnaire 9 (PHQ-9), Generalized Anxiety Disorder 7 (GAD-7) assessment, Montreal Cognitive Assessment (MoCA), and Thing Categories Test (TCT) were used to evaluate patients with RA, as well as the control group.

Results: Twenty patients with RA and 20 controls were tested, with 7 and 4 men, and 13 and 16 women in the study and control group, respectively. Average scores in TCT at three minutes were 7.50 (IQR6.0-10.0) and 6.0 (IQR3.0-8.0) for category “blue”; 17.50 (IQR15.0-19.0) and 16.0 (10.0-18.0) for category “round” in the control and study group, respectively. A statistically significant difference was established between the study and the control group in TCT for the category “blue” (p<0.025). The average score for GAD7 was 2.0 (IQR 0.0-5.75) and 3.0 (IQR0.50-6.00) in the control and study group, respectively. The average score for PHQ-9 was 2.0 (IQR0.25-4.75) and 4.0 (IQR2.00-5.50) in the control and study group, respectively. Finally, the average score for the MoCA scale was 27.0 (IQR25.25-28.00) and 26.0 (IQR23.50-28.00) in the control and study group, respectively.

Conclusion: Preliminary evidence suggests that RA at least partially affects the cognitive domain of ideational fluency. However, further research with larger experimental groups is needed to provide more conclusive evidence.

Keywords: Cognitive impairment, rheumatoid arthritis, depression, anxiety, ideational fluency, retrieval ability, Cattell-Horn-- Carroll theory.

[1]
Tobón GJ, Youinou P, Saraux A. The environment, geo-epidemiology, and autoimmune disease: Rheumatoid arthritis. J Autoimmun 2010; 35(1): 10-4.
[http://dx.doi.org/10.1016/j.jaut.2009.12.009] [PMID: 20080387]
[2]
Minichiello E, Semerano L, Boissier M-C. Time trends in the incidence, prevalence, and severity of rheumatoid arthritis: A systematic literature review. Joint Bone Spine 2016; 83(6): 625-30.
[http://dx.doi.org/10.1016/j.jbspin.2016.07.007] [PMID: 27616690]
[3]
Vos T, Abajobir AA, Abate KH, Abbafati C, Abbas KM, Abd-Allah F, et al. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017; 390(10100): 1211-59.
[http://dx.doi.org/10.1016/S0140-6736(17)32154-2] [PMID: 28919117]
[4]
Matcham F, Rayner L, Steer S, Hotopf M. The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford) 2013; 52(12): 2136-48.
[http://dx.doi.org/10.1093/rheumatology/ket169] [PMID: 24003249]
[5]
Somers JM, Goldner EM, Waraich P, Hsu L. Prevalence and incidence studies of anxiety disorders: a systematic review of the literature. Can J Psychiatry 2006; 51(2): 100-13.
[http://dx.doi.org/10.1177/070674370605100206] [PMID: 16989109]
[6]
Qiu XJ, Zhang XL, Cai LS, et al. Rheumatoid arthritis and risk of anxiety: a meta-analysis of cohort studies. Clin Rheumatol 2019; 38(8): 2053-61.
[http://dx.doi.org/10.1007/s10067-019-04502-8] [PMID: 30924010]
[7]
Leslie B, Crowe SF. Cognitive functioning in systemic lupus erythematosus: a meta-analysis. Lupus 2018; 27(6): 920-9.
[http://dx.doi.org/10.1177/0961203317751859] [PMID: 29310536]
[8]
Amaral TN, Peres FA, Lapa AT, Marques-Neto JF, Appenzeller S. Neurologic involvement in scleroderma: a systematic review. Semin Arthritis Rheum 2013; 43(3): 335-47.
[http://dx.doi.org/10.1016/j.semarthrit.2013.05.002] [PMID: 23827688]
[9]
Khedr EM, El Fetoh NA, Gamal RM, Elzohri MH, Azoz NMA, Furst DE. Evaluation of cognitive function in systemic sclerosis patients: a pilot study. Clin Rheumatol 2020; 39(5): 1551-9.
[http://dx.doi.org/10.1007/s10067-019-04884-9] [PMID: 31902028]
[10]
Meade T, Manolios N, Cumming SR, Conaghan PG, Katz P. Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review. Arthritis Care Res (Hoboken) 2018; 70(1): 39-52.
[http://dx.doi.org/10.1002/acr.23243] [PMID: 28371512]
[11]
Auyeung TW, Kwok T, Lee J, Leung PC, Leung J, Woo J. Functional decline in cognitive impairment--the relationship between physical and cognitive function. Neuroepidemiology 2008; 31(3): 167-73.
[http://dx.doi.org/10.1159/000154929] [PMID: 18784415]
[12]
Baird C, Lovell J, Johnson M, Shiell K, Ibrahim JE. The impact of cognitive impairment on self-management in chronic obstructive pulmonary disease: A systematic review. Respir Med 2017; 129: 130-9.
[http://dx.doi.org/10.1016/j.rmed.2017.06.006] [PMID: 28732820]
[13]
Hill NL, McDermott C, Mogle J, et al. Subjective cognitive impairment and quality of life: a systematic review. Int Psychogeriatr 2017; 29(12): 1965-77.
[http://dx.doi.org/10.1017/S1041610217001636] [PMID: 28829003]
[14]
Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 1993; 36(12): 1681-90.
[http://dx.doi.org/10.1002/art.1780361206] [PMID: 8250987]
[15]
Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41(9): 1552-63.
[http://dx.doi.org/10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W] [PMID: 9751087]
[16]
Manson J, Nistala K. Rheumatoid Arthritis.Encyclopedia of ImmunobiologyElsevier. 2016; pp. 212-8.
[http://dx.doi.org/10.1016/B978-0-12-374279-7.15004-0]
[17]
Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992; 89(20): 9784-8.
[http://dx.doi.org/10.1073/pnas.89.20.9784] [PMID: 1409699]
[18]
Holmes C, Cunningham C, Zotova E, et al. Systemic inflammation and disease progression in Alzheimer disease. Neurology 2009; 73(10): 768-74.
[http://dx.doi.org/10.1212/WNL.0b013e3181b6bb95] [PMID: 19738171]
[19]
Marsland AL, Gianaros PJ, Abramowitch SM, Manuck SB, Hariri AR. Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults. Biol Psychiatry 2008; 64(6): 484-90.
[http://dx.doi.org/10.1016/j.biopsych.2008.04.016] [PMID: 18514163]
[20]
Leonard BE. Inflammation and depression: a causal or coincidental link to the pathophysiology? Acta Neuropsychiatr 2018; 30(1): 1-16.
[http://dx.doi.org/10.1017/neu.2016.69] [PMID: 28112061]
[21]
Dowlati Y, Herrmann N, Swardfager W, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry 2010; 67(5): 446-57.
[http://dx.doi.org/10.1016/j.biopsych.2009.09.033] [PMID: 20015486]
[22]
Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of Alzheimer’s Disease: A Nested Case-Control Analysis. CNS Drugs 2016; 30(11): 1111-20.
[http://dx.doi.org/10.1007/s40263-016-0374-z] [PMID: 27470609]
[23]
Pache M, Schwarz HA, Kaiser HJ, et al. Elevated plasma endothelin-1 levels and vascular dysregulation in patients with rheumatoid arthritis. Med Sci Monit 2002; 8(9): CR616-9.
[PMID: 12218941]
[24]
Yoshida H, Imafuku Y, Ohhara M, et al. Endothelin-1 production by human synoviocytes. Ann Clin Biochem 1998; 35(Pt 2): 290-4.
[http://dx.doi.org/10.1177/000456329803500215] [PMID: 9547903]
[25]
Nakayama K, Ishigai Y, Uchida H, Tanaka Y. Potentiation by endothelin-1 of 5-hydroxytryptamine-induced contraction in coronary artery of the pig. Br J Pharmacol 1991; 104(4): 978-86.
[http://dx.doi.org/10.1111/j.1476-5381.1991.tb12536.x] [PMID: 1810605]
[26]
Faraco G, Moraga A, Moore J, Anrather J, Pickel VM, Iadecola C. Circulating endothelin-1 alters critical mechanisms regulating cerebral microcirculation. Hypertension 2013; 62(4): 759-66.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.113.01761] [PMID: 23959559]
[27]
D’haeseleer M, Hostenbach S, Peeters I, et al. Cerebral hypoperfusion: a new pathophysiologic concept in multiple sclerosis? J Cereb Blood Flow Metab 2015; 35(9): 1406-10.
[http://dx.doi.org/10.1038/jcbfm.2015.131] [PMID: 26104292]
[28]
Freeman BD, Martins YC, Akide-Ndunge OB, Bruno FP, Wang H, Tanowitz HB, et al. Endothelin-1 mediates brain microvascular dysfunction leading to long-term cognitive impairment in a model of experimental cerebral malaria.Seydel KB, editor PLOS Pathog. 2016; 12(3): p. e1005477.
[http://dx.doi.org/10.1371/journal.ppat.1005477]
[29]
Julio-Pieper M, Bravo JA. Intestinal barrier and behavior.International review of neurobiology. Elsevier 2016; pp. 127-41. Internet.
[30]
Moriarty O, McGuire BE, Finn DP. The effect of pain on cognitive function: a review of clinical and preclinical research. Prog Neurobiol 2011; 93(3): 385-404.
[http://dx.doi.org/10.1016/j.pneurobio.2011.01.002] [PMID: 21216272]
[31]
Woolf CJ, Costigan M. Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci USA 1999; 96(14): 7723-30.
[http://dx.doi.org/10.1073/pnas.96.14.7723] [PMID: 10393888]
[32]
Jolliffe VA, Anand P, Kidd BL. Assessment of cutaneous sensory and autonomic axon reflexes in rheumatoid arthritis. Ann Rheum Dis 1995; 54(4): 251-5.
[http://dx.doi.org/10.1136/ard.54.4.251] [PMID: 7763100]
[33]
Morris VH, Cruwys SC, Kidd BL. Characterisation of capsaicin-induced mechanical hyperalgesia as a marker for altered nociceptive processing in patients with rheumatoid arthritis. Pain 1997; 71(2): 179-86.
[http://dx.doi.org/10.1016/S0304-3959(97)03361-7] [PMID: 9211479]
[34]
Poh LW, He H-G, Lee CSC, Cheung PP, Chan W-CS. An integrative review of experiences of patients with rheumatoid arthritis. Int Nurs Rev 2015; 62(2): 231-47.
[http://dx.doi.org/10.1111/inr.12166] [PMID: 25612222]
[35]
Fauth EB, Schwartz S, Tschanz JT, Østbye T, Corcoran C, Norton MC. Baseline disability in activities of daily living predicts dementia risk even after controlling for baseline global cognitive ability and depressive symptoms. Int J Geriatr Psychiatry 2013; 28(6): 597-606.
[http://dx.doi.org/10.1002/gps.3865] [PMID: 22968965]
[36]
Wilkins CH, Roe CM, Morris JC, Galvin JE. Mild physical impairment predicts future diagnosis of dementia of the Alzheimer’s type. J Am Geriatr Soc 2013; 61(7): 1055-9.
[http://dx.doi.org/10.1111/jgs.12255] [PMID: 23647233]
[37]
Alzheimer’s Disease Anti-inflammatory Prevention Trial Research Group. Results of a follow-up study to the randomized Alzheimer’s Disease Anti-inflammatory Prevention Trial (ADAPT). Alzheimers Dement 2013; 9(6): 714-23.
[http://dx.doi.org/10.1016/j.jalz.2012.11.012] [PMID: 23562431]
[38]
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48(3): 626-32.
[http://dx.doi.org/10.1212/WNL.48.3.626] [PMID: 9065537]
[39]
Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology. Neurology 2008; 70(23): 2219-25.
[http://dx.doi.org/10.1212/01.wnl.0000313813.48505.86] [PMID: 18519870]
[40]
Nielsen JB. Drivsholm Aa, Fischer F, Brøchner-Mortensen K. Long-term Treatment with Corticosteroids in Rheumatoid Arthritis: (Over a Period of 9 to 12 Years). Acta Med Scand 2009; 173(2): 177-83.
[http://dx.doi.org/10.1111/j.0954-6820.1963.tb16519.x]
[41]
The Boston Collaborative Drug Surveillance Program. Acute adverse reactions to prednisone in relation to dosage. Clin Pharmacol Ther 1972; 13(5): 694-8.
[PMID: 5053810]
[42]
Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review. Eur J Med Chem 2018; 158: 502-16.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.027] [PMID: 30243154]
[43]
Watanabe K, Arakawa Y, Oguma E, et al. Characteristics of methotrexate-induced stroke-like neurotoxicity. Int J Hematol 2018; 108(6): 630-6.
[http://dx.doi.org/10.1007/s12185-018-2525-0] [PMID: 30182170]
[44]
Gibson EM, Nagaraja S, Ocampo A, et al. Methotrexate Chemotherapy Induces Persistent Tri-glial Dysregulation that Underlies Chemotherapy-Related Cognitive Impairment. Cell 2019; 176(1-2): 43-55.e13.
[http://dx.doi.org/10.1016/j.cell.2018.10.049] [PMID: 30528430]
[45]
Salouage I, El Aïdli S, Cherif F, Kastalli S, Zaiem A, Daghfous R. Sulfasalazine-induced aseptic meningitis with positive rechallenge: a case report and review of the literature. Therapie 2013; 68(6): 423-6.
[http://dx.doi.org/10.2515/therapie/2013065] [PMID: 24356191]
[46]
Alfaro-Lara R, Espinosa-Ortega HF, Arce-Salinas CA. PRECIS study group, all physicians belong to Division of Internal Medicine. Hospital Central Sur de Pemex. Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis. Reumatol Clin 2019; 15(3): 133-9.
[http://dx.doi.org/10.1016/j.reuma.2017.07.020] [PMID: 28867467]
[47]
Raftery G, He J, Pearce R, et al. Disease activity and cognition in rheumatoid arthritis: an open label pilot study. Arthritis Res Ther 2012; 14(6): R263.
[http://dx.doi.org/10.1186/ar4108] [PMID: 23211089]
[48]
Hoving JL, Bartelds GM, Sluiter JK, et al. Perceived work ability, quality of life, and fatigue in patients with rheumatoid arthritis after a 6-month course of TNF inhibitors: prospective intervention study and partial economic evaluation. Scand J Rheumatol 2009; 38(4): 246-50.
[http://dx.doi.org/10.1080/03009740902748264] [PMID: 19337948]
[49]
Decourt B, Lahiri D, Sabbagh M. Targeting Tumor Necrosis Factor Alpha for Alzheimer’s Disease. Curr Alzheimer Res 2016; 13(999): 1-1.
[http://dx.doi.org/10.2174/1567205013666160930110551] [PMID: 27697064]
[50]
Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). Intern Med 2009; 48(15): 1307-9.
[http://dx.doi.org/10.2169/internalmedicine.48.1926] [PMID: 19652436]
[51]
Yamaguchi Y, Furukawa K, Yamamoto T, Takahashi Y, Tanaka K, Takahashi M. Multifocal encephalopathy and autoimmune-mediated limbic encephalitis following tocilizumab therapy. Intern Med 2014; 53(8): 879-82.
[http://dx.doi.org/10.2169/internalmedicine.53.0615] [PMID: 24739610]
[52]
McGrew KS. CHC theory and the human cognitive abilities project: Standing on the shoulders of the giants of psychometric intelligence research. Intelligence 2009; 37(1): 1-10.
[http://dx.doi.org/10.1016/j.intell.2008.08.004]
[53]
Flanagan DP, Harrison PL, Eds. Contemporary intellectual assessment: theories, tests, and issues. (3rd ed.), New York: Guilford Press 2012.
[54]
Caemmerer JM, Keith TZ, Reynolds MR. Beyond individual intelligence tests: Application of Cattell-Horn-Carroll Theory. Intelligence 2020; 79: 101433.
[http://dx.doi.org/10.1016/j.intell.2020.101433]
[55]
Jewsbury PA, Bowden SC, Duff K. The cattell–horn–carroll model of cognition for clinical assessment. J Psychoed Assess 2017; 35(6): 547-67.
[http://dx.doi.org/10.1177/0734282916651360]
[56]
Flanagan DP, Harrison PL, Eds. Contemporary intellectual assessment: theories, tests, and issues. (4rd ed..). New York: Guilford Press 2012; pp. 83-7..
[57]
Reitz C, Tang M-X, Manly J, Mayeux R, Luchsinger JA. Hypertension and the risk of mild cognitive impairment. Arch Neurol 2007; 64(12): 1734-40.
[http://dx.doi.org/10.1001/archneur.64.12.1734] [PMID: 18071036]
[58]
Rancans E, Trapencieris M, Ivanovs R, Vrublevska J. Validity of the PHQ-9 and PHQ-2 to screen for depression in nationwide primary care population in Latvia. Ann Gen Psychiatry 2018; 17(1): 33.
[http://dx.doi.org/10.1186/s12991-018-0203-5] [PMID: 30083220]
[59]
Spitzer RL, Kroenke K, Williams JBW, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166(10): 1092-7.
[http://dx.doi.org/10.1001/archinte.166.10.1092] [PMID: 16717171]
[60]
Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 53(4): 695-9.
[http://dx.doi.org/10.1111/j.1532-5415.2005.53221.x] [PMID: 15817019]
[61]
Vannorsdall TD, Maroof DA, Gordon B, Schretlen DJ. Ideational fluency as a domain of human cognition. Neuropsychology 2012; 26(3): 400-5.
[http://dx.doi.org/10.1037/a0027989] [PMID: 22563877]
[62]
Ekstrom RB, French JW, Harman MH, Dermen D. Manual for kit of factor-referenced cognitive tests. Princeton, NJ: Educational Testing Service 1976..
[63]
Leonard BE. Impact of inflammation on neurotransmitter changes in major depression: an insight into the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2014; 48: 261-7.
[http://dx.doi.org/10.1016/j.pnpbp.2013.10.018] [PMID: 24189118]
[64]
Valdez P, Mehrabian A. Effects of color on emotions. J Exp Psychol Gen 1994; 123(4): 394-409.
[http://dx.doi.org/10.1037/0096-3445.123.4.394] [PMID: 7996122]
[65]
Palmer SE, Schloss KB. An ecological valence theory of human color preference. Proc Natl Acad Sci USA 2010; 107(19): 8877-82.
[http://dx.doi.org/10.1073/pnas.0906172107] [PMID: 20421475]
[66]
Šķilters J, Zariņa L, Bāliņa S, Baumgarte D. Impact of Demographic Differences on Color Preferences in the Interface Design of e-Services in Latvia.Lupeikiene A, Vasilecas O, Dzemyda G, editors Databases and Information SystemsCham: Springer International Publishing. 2018; 838: pp. 106-20.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 2
Year: 2021
Published on: 19 November, 2020
Page: [205 - 212]
Pages: 8
DOI: 10.2174/1573397116666201119145640
Price: $65

Article Metrics

PDF: 50
HTML: 2